SG 005
Alternative Names: SG-005Latest Information Update: 09 Jan 2026
At a glance
- Originator SineuGene Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action Gene silencing; RNA-binding protein FUS expression inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Amyotrophic lateral sclerosis
Most Recent Events
- 10 Oct 2025 Early research in Amyotrophic lateral sclerosis in China (Parenteral) (Prior to October 2025) (SineuGene Therapeutics pipeline, October 2025)